Remegen Co. Ltd.

Remegen Co. Ltd. focuses its clinical research on moderately to severely active systemic lupus erythematosus, with trials centered on adult patients who have an inadequate response to standard of care therapy.

• Autoimmune disease management
• Systemic lupus erythematosus treatment
• Standard of care-refractory disease

The sponsor’s trial activity in this area is directed toward evaluating therapeutic options for persistent disease activity in adult patients with active SLE.